FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy
Journal of Cellular and Molecular Medicine · 2025-01 · 29 (1)
DOI: 10.1111/jcmm.70169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 11.01.2025. Verfasst von Amanda Eckstrom und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Killer Cells, Natural, Leukemia, Myeloid, Acute, Induced Pluripotent Stem Cells. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Fate Therapeutics, Inc., National Cancer Institute.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Induced pluripotent stem cell (iPSC)–derived natural killer (NK) cells offer an opportunity for a standardized, off‐the‐shelf treatment with the potential to treat a wider population of acute myeloid leukaemia (AML) patients than the current standard of care. FT538 iPSC‐NKs express a high‐affinity, noncleavable CD16 to maximize antibody dependent cellular cytotoxicity, a CD38 knockout to improve metabolic fitness, and an IL‐15/IL‐15 receptor fusion preventing the need for cytokine administration, the main source of adverse effects in NK cell–based therapies. Here, we sought to evaluate the potential of FT538 iPSC‐NKs as a therapy for AML through their effect on AML cell lines and primary AML cells. We observed that FT538 iPSC‐NKs induce effector‐to‐target cell ratio dependent apoptosis in cell lines and primary AML cells, including cells from high‐risk patients. Flow cytometric analysis revealed that FT538 iPSC‐NKs induce AML cell death when combined with the AML therapies: cytarabine, venetoclax and gilteritinib. Moreover, cytarabine did not affect FT538 iPSC‐NK viability, suggesting that iPSC‐derived NK therapies and chemotherapy may be a promising treatment combination. This study provides the basis for further study of iPSC‐derived NK cell therapies as a treatment option for high‐risk AML patients, particularly those with disease resistant to standard therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Fate Therapeutics, Inc., San Diego, California, USA.
- Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
ORCID-Profile: Adishwar Rao, V Lokesh Battula
Förderung
- NCI NIH HHS
- Fate Therapeutics, Inc.
- National Cancer Institute
Zitieren
APA
Eckstrom, A., Tyagi, A., Mahmood, S., Wong, L., Valamehr, B., Rao, A., Agrawal, A., Siddiqui, M., & Battula, V. L. (2025). FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy. Journal of Cellular and Molecular Medicine, 29(1). https://doi.org/10.1111/jcmm.70169
Vancouver
Eckstrom A, Tyagi A, Mahmood S, Wong L, Valamehr B, Rao A, et al. FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy. Journal of Cellular and Molecular Medicine. 2025;29(1). doi:10.1111/jcmm.70169
BibTeX
@article{Eckstrom2025,
author = {Eckstrom, Amanda and Tyagi, Anudishi and Mahmood, Sajid and Wong, Lilly and Valamehr, Bahram and Rao, Adishwar and Agrawal, Akriti and Siddiqui, Maryam and Battula, V Lokesh},
title = {FT538 , iPSC ‐derived NK cells, enhance AML cell killing when combined with chemotherapy},
journal = {Journal of Cellular and Molecular Medicine},
year = {2025},
volume = {29},
number = {1},
doi = {10.1111/jcmm.70169}
}
EUVIMED